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We appreciate the comment of Lackner and M€uller-Call-
eja on our recent publication on laboratory criteria of
antiphospholipid syndrome (APS) [1]. In their comment,
an advocacy for cofactor independent anticardiolipin
antibodies (aCL) is made [2]. In our communication, we
recommend testing for b2 glycoprotein I (b2GPI)-depen-
dent aCL as laboratory criteria for APS primarily to avoid
false positive classification of patients as having APS and
thereby prevent unnecessary treatment. Our focus on
b2GPI-dependent aCL is intended to avoid infection-
related aCL that are not associated with clinical symptoms
associated with APS. The aPL testing profile we
recommend has been proven to be associated with APS in
in vitro and in vivo studies [3,4]. Lackner and M€uller-Calleja
question whether cofactor-independent antiphospholipid
antibodies (aPL) play an equally important role and are
not minor in comparison to b2GPI-dependent aPL [5].
The two questions raised by Lackner et al. are:
1 How is detection of non-cofactor-related aCL avoided?
We acknowledge that aCL immunoassays detect an
array of autoantibodies, including cofactor-dependent and
cofactor-independent antibodies. What we are recommend-
ing against are aCL assays that are specifically designed to
avoid the cofactor b2GPI in the assay, given the limited
data available for the clinical relevance of b2GPI-indepen-
dent aCL. Proteins other than b2GPI can bind cardiolipin
in an ELISA assay [6] and the demonstration that aCL are
authentic antibodies directed to cardiolipin is difficult [7].
The presence of aCL in the absence of b2GPI means that
b2GPI is not the cofactor, but other cofactors may be pre-
sent. Some patients with APS have circulating antibodies
to other cardiolipin-binding proteins, including comple-
ment factor C4 and Factor H [6].
We agree that omission of aCL testing from the clinical
investigation of APS could lead to a failure to diagnose
APS in a proportion of patients. aCL can be significantly
associated with an increased risk of thrombosis, as illus-
trated in the meta-analysis that is mentioned [8], among
others. In the global forest plot in this report, the odds
ratio is 1.75–4.00 for aCL and 1.51–6.44 for b2GPI-anti-
bodies (ab2GPI) [8]. However, no details are given on the
type of aCL assays used in the studies included in this
meta-analysis, although most probably included aCL
assays that are b2GPI dependent. The role of aCL was
also underlined by referring to the article of Nash et al.
from 2004 [9]. In this study an in-house ELISA with 10%
fetal calf serum as blocking agent was used [10], which is
a source of b2GPI. Moreover, we also have the experi-
ence that a b2GPI-dependent aCL immunoassay can be
as specific as an ab2GPI assay [11,12].
2 Why should non-cofactor-related aCL be avoided?
Although animal models and pathogenic pathways
have been described showing that cofactor-independent
aPL may induce thrombosis or placental complications
[13,14], most experts in the field agree that b2GPI is the
main player in pathophysiology of APS [15–17]. Data
concerning the clinical relevance of cofactor-independent
aPL are limited in humans. Also, in contrast to infectious
aCL, autoimmune aCL antibodies react with phospho-
lipids mainly by binding to plasma b2GPI. Although
there is a well-documented link between the risk of
thrombosis and the presence of b2GPI-dependent aCL,
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the pathological impact of other aPL is less clear. Besides
the analytical difficulty of detecting these cofactor-inde-
pendent antibodies, they may indicate diseases different
from APS that may require different treatment.
Cofactor dependency has also been demonstrated for
lupus anticoagulants (LAC): when Pengo et al. tried to
purify LAC by means of cardiolipin liposomes [18], it was
possible only using patient plasma and not Protein A
purified IgG. This supported that LAC activity in most
patients is mediated by a plasma protein, which was iden-
tified as b2GPI. Thus LAC (the factor most associated
with thromboembolic events) is cofactor dependent, and
although cofactor (b2GPI)-independent LAC exists, it
probably indicates a different disease state [19,20].
aCL determination in our recommendation is of help
in confirming the positivity of ab2GPI of the same iso-
type. Positive aCL in the absence of ab2GPI should be
interpreted with caution. False positive results are fre-
quent, depending on solid phase assays by different man-
ufacturers [21,22] (cardiolipin plus bovine b2GPI,
cardiolipin plus human b2GPI, cardiolipin alone). With
the current assays, patients with an antibody profile with
triple positivity are at the highest risk of thrombosis
[3,23,24]. With these assays, we are measuring b2GPI-
dependent antibodies, confirmed by the fact that most of
these patients are also positive for a subgroup of ab2GPI,
the antibodies specifically directed against domain I of
b2GPI [25,26].
Recommendations of the SSC aim to be straightfor-
ward, clear and concise reports that help workers in the
field in their daily practice. Standardization of solid phase
assays is still a problem. Adding a variety of assays to
classification criteria introduces confusion and opens the
way to a proliferation of irrelevant diagnostic tools lead-
ing to false positive results. Therefore, we restricted our
recommendations to assays with evidence of detecting
pathogenic and clinically relevant autoantibodies.
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